SIGA Receives Approval from the FDA for Intravenous (IV) Formulation of TPOXX® (tecovirimat)
SIGA Technologies, Inc. (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, announced that the U.S. Food and Drug Administration (FDA) approved the int...